The role of v2 receptor antagonists in the treatment of hyponatremia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Cisplatin-Induced Acute Kidney Injury and Renal Salt Wasting Syndrome.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021
   Article
2. Duloxetine and Angiotensin II Receptor Blocker Combination Potentially Induce Severe Hyponatremia in an Elderly Woman.Internal medicine (Tokyo, Japan) · 2019
   Article
3. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?World journal of gastroenterology · 2015
   Review
4. Management of severe hyponatremia: infusion of hypertonic saline and desmopressin or infusion of vasopressin inhibitors?The American journal of the medical sciences · 2014
   Review
5. Tolvaptan Use to Treat SIADH in a Child.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.